AI in life sciences raises various patent law considerations, including subject matter eligibility, novelty/obviousness, and ...

Sitryx CEO Iain Kilty describes the biopharmaceutical industry effort to go beyond immunosuppression in autoimmune and ...

Sponsored genetic testing programs can run afoul of federal laws, including the FCA and AKS, if not designed correctly. Experts at Morrison Foerster share best practices for compliance.

The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering ...

The onset of the new U.S. presidential administration brings with it sweeping changes to U.S. policy related to artificial intelligence (AI). As a first step, the Trump administration revoked the ...

Six of the seven blockbuster biotherapeutics belonging to Big Pharma have roots to small biotechs (see Table 1). So too does Tim Charlebois, Ph.D., VP of technology and innovation strategy within ...

Industry Leader articles are written by executives at biopharma companies, consultancies, research firms, and companies that provide services or products to sponsors. The topics are nonpromotional and ...

Life Science Leader is an essential business publication for life science executives who work at everything from emerging biotechs to large pharmaceutical companies. Our content is designed to inform ...

The North Carolina Biotechnology Center leads life sciences economic development for North Carolina by supporting the progression of ideas from research lab to the marketplace. NCBiotech invests in ...

On this episode of the Business of Biotech, Life Science Leader's Ben Comer joins to co-host a conversation with Dr. Roet that goes deep on his company's genetic medicine approach to ALS, and even ...